Why this new colorectal cancer alliance matters for Natera stock
Natera (NTRA) just announced a colorectal cancer collaboration with TransCode Therapeutics that centers on its Signatera test to identify molecular residual disease and feed eligible patients into a Phase 2a trial.
The arrangement links Natera’s MRD testing directly to trial enrollment criteria for TransCode’s TTX-MC138 candidate, tying the diagnostics group more tightly to drug development workflows in colorectal cancer and early feasibility studies.
Natera’s colorectal cancer alliance lands after a strong run in the stock, with a 90-day share price return of 60.16% and a year-to-date share price gain of 76.52%, while the 1-year total shareholder return of 110.15% and very large 3-year total shareholder return suggest momentum has been building rather than fading.
Spot emerging oncology leaders by scanning the 34 healthcare AI stocks that echo Natera’s push into precision cancer trials.Natera now trades just below the average analyst target, yet still at a sizeable discount to some intrinsic value estimates. After this kind of run, where does a fair entry range realistically sit?
Most Popular Narrative: Fairly Valued
Natera closed at $403.95, almost exactly in line with the narrative fair value of $403.89, so the story today is about expectations rather than a discount.
Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, supporting potential revenue expansion.
See why 18 investors see Natera as 0% overvalued.
Result: Fair Value of $403.89 (ABOUT RIGHT)
Still, the fair value story for Natera can crack if reimbursement policies tighten around prenatal testing or if high R&D spend keeps profitability further out than analysts expect.
Find out about the key risks to this Natera narrative.
Another View: What the SWS DCF model says about Natera
While the current price is close to the narrative fair value of $403.89, the SWS DCF model points a different way. It estimates Natera at $604.57 per share, which implies the stock trades at a steep discount. If that gap ever narrows, which framework will be closer to reality?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 28 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this all sounds optimistic around Natera, treat it as a starting point and pressure test the numbers yourself while sentiment is still fresh. To see what investors are excited about, take a closer look at 3 key rewards.
Looking for more investment ideas beyond Natera?
If Natera has your attention, do not stop here. Broaden your watchlist with other stocks that pass clear, numbers based filters built to highlight quality.
- Target dependable balance sheets by running your own checks through the list of solid balance sheet and fundamentals (24 results).
- Hunt for mispriced opportunities using the 28 high quality undervalued stocks before other investors catch on.
- Spot potential future market favorites early by scanning the 21 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com